You are currently browsing the tag archive for the ‘Jonathan Kipnis’ tag.
by Carol Morton
Three years ago, a study showed that a bone marrow transplant performed in pre-symptomatic male mice models of Rett Syndrome substantially extended their lives and reduced symptoms of disease. The unexpected findings caught the attention of Rett researchers, physicians, and parents.
Seeking to validate the results and therefore strengthen the case for clinical studies, four other research groups launched their own mouse studies. In independent experiments, each lab was unable to replicate the original findings.
The researchers combined their results into a single paper, published May 20 in Nature, the same journal that published the original positive results. The new study is posted online only as a “brief communication arising,” a category for new scientific data that challenge the findings of an original research paper in the journal, according to Veronique Kiemer, executive editor of the Nature Publishing Group.
The new paper means that bone marrow transplants may not be a viable therapeutic option, but the pair of papers could point the way to new insights into Rett and ways to fix it, said Monica Carson, a neuroimmunologist at the University of California, Riverside, who was not involved in any of the studies.
“The key is that both answers are possible,” Carson said. “ It’s important to figure out the differences between the papers.”
The original paper came from the lab of Jonathan Kipnis, a neuroimmunologist at University of Virginia in Charlottesville. Kipnis and his colleagues explore the role of the immune system in healthy and diseased brains. No stranger to controversial findings, he has shown that T cells closely surrounding the brain are somehow crucial to normal cognitive function.
In fact, the team first conducted the transplants to test the idea that inadequate T cells in Rett mice might explain their cognitive impairment. “We proved our original hypothesis wrong,” Kipnis said. But with new immune cells, the mice lived much longer. Most cases of Rett can be traced to a malfunctioning gene on the X chromosome called methyl-CpG-binding protein 2 (MeCP2). A transplant fixed the faulty gene in the mice’s immune cells.
How was a new immune system exerting a protective effect? A clue came from stem cell transplant studies for Alzheimer’s disease, where another kind of circulating immune cell, called monocytes or macrophages, lodge in the brain and clear away debris that may cause neurodegeneration. After further experiments, Kipnis and his co-authors proposed that monocytes with good MeCP2 genes also migrated to the brain in the Rett models and helped their brain-dwelling microglia cousins in some unknown way.
Last month, the Kipnis team reported the first molecular and cellular evidence that MeCP2 controls gene expression in macrophages and that some types of macrophages in the brain and throughout the body may be especially vulnerable early in disease. “This work is a beautiful example of how the immune and nervous systems are intimately associated, sharing common molecular pathways and potentially affecting the function of one another in many dynamic ways,” according to a commentary published with the paper.
The original paper was funded by RSRT. Given the serious nature and risk of a bone marrow transplant, RSRT felt it was crucial to reproduce the findings before supporting any clinical trials. RSRT awarded funding to Andrew Pieper, now at the University of Iowa, who had provided the original mice for the Kipnis study, and Antonio Bedalov, at the Fred Hutchinson Cancer Research Center, a scientist and oncologist, who works with bone marrow transplant patients.
Independently, Peter Huppke, at University Medical Center Gottingen in Germany, and Jeffrey Neul, now at University of California, San Diego, also attempted replications. None of the four labs saw the significant effects seen by Kipnis.
For his part, Kipnis interprets the new paper differently. “Most importantly, it confirms our initial findings, although not as dramatically,” he said, pointing to a small increased lifespan effect that could be seen if two figures were combined. He and two lead co-authors of the original paper have written a detailed response in the comment section for the paper. It outlines suspected issues with the new paper, including mice that may have inadvertently acquired a mixed genetic background and may therefore have a version of graft versus host disease (GVHD) which would have confounded the results. This would be analogous to a person receiving bone marrow that was not a tissue match. Bedalov denied that possibility, saying GVHD would be obvious because the mice would have additional symptoms.
The first mouse study had prompted clinical investigators to add boys with Rett to a hematopoietic stem cell transplant protocol last year. Boys with classic Rett mutations have more severe disease and usually die by age 2. Based on the new findings, the trial has withdrawn Rett as a disease eligibility, wrote principal investigator Weston Miller at the University of Minnesota in an email. No boys with Rett had enrolled in the trial.
Other researchers contacted by RSRT applaud the attempt to replicate the bone marrow transplant findings before considering clinical trials, but they see a more important unfolding story is the role of the immune system in Rett disease biology.
Looking ahead, “discrepancies between labs do occur,” Kipnis and his co-authors wrote, “and understanding the cause of varying results can ultimately lead to an even better understanding of the scientific or disease-related process in question.”
Jonathan Kipnis and his lab members Noel Derecki and James Cronk authored the recent Nature paper entitled Wild type microglia arrest pathology in a mouse model of Rett Syndrome. Watch the videos below for some insight into what makes them tick.
Jonathan Kipnis, Ph.D.
Noël Derecki, Ph.D.
The recent publication of the Kipnis paper in Nature has generated understandable excitement and questions in the Rett community. Email and Facebook are difficult vehicles for providing proper answers. Rett Syndrome is complex, and so is the research; this work doesn’t lend itself to sound bites. I know Rett mothers and fathers are often tired and overworked, but I encourage you to find fifteen minutes to sit down together with a cup of coffee, listen carefully to what these researchers are discussing in the video interview, and come away more deeply informed.
The paper has already been euphemistically coined the bone marrow transplant paper. I’ve occasionally called it that myself, sometimes in the presence of Dr. Kipnis, who promptly says, “Please don’t call it that. There is so much more information in that paper than just the bone marrow experiments.” He’s right. In fact, there is enough material to have generated multiple publications.
The paper is attracting an unusual amount of attention in the scientific community, and this is bound to stimulate more interest in Rett Syndrome and the role of the immune system in neurological disorders. The bone marrow transplant result is understandably what families gravitate to because of the potential for clinical application, but it’s important not to ignore the other findings, because they too could point to eventual treatments. In fact, it is my fervent hope that in time, new discoveries will make it possible to manipulate the immune system through a safer route.
Bone marrow transplants (BMT) have been used since 1968 to treat an increasingly wide range of disease, including cancers, metabolic diseases, inherited red cell disorders and immune disorders. The treatment can be lifesaving. It can also be fatal. Accompanied by chemotherapy and/or radiation treatment, BMT is a serious and grueling procedure with significant side effects. The combined expertise of specialists in pediatric BMT, as well as in Rett Syndrome, together with basic scientists is crucial to minimizing risk as much as possible.
As part of a fact-gathering process, RSRT has been facilitating talks between top pediatric transplant centers and Sasha Djukic, Director of the Rett Syndrome Center at the Children’s Hospital at Montefiore, Jonathan Kipnis and his lab members and, most recently, NIH. Discussion includes defining the data needed to consider clinical trials. This must be completed and thoroughly evaluated in order to design the best possible treatment protocol. Independent confirmation of the results achieved by Dr. Kipnis and his team is a standard requirement; this work is already underway. Further experiments in the Kipnis lab itself are ongoing, and we can expect more new information to emerge.
It is perhaps timely for me to reiterate that RSRT is very aggressive about research, and conservative about clinical application. I want to be crystal clear on one thing – parents should not take it upon themselves to pursue BMT for their child. As the mother of a severely afflicted daughter, I understand all too well the desperation for treatment. As Executive Director of RSRT, I understand equally well the importance of applying meticulous due diligence. RSRT does this in all the work we undertake, the projects we review, our financial decisions, and certainly in our approach to clinical trials.
I share your excitement, your urgency and your trepidation, and RSRT will continue to inform you of new developments as they unfold.
– Monica Coenraads
Executive Director, RSRT
A paper published online today in the high-profile journal, Nature, describes the results of using a bone marrow transplant to dramatically stop the development of symptoms in pre-symptomatic male and female mouse models of Rett Syndrome. The work was undertaken in the neuroimmunology laboratory of Jonathan Kipnis, Ph.D. and his team at the University of Virginia.
That a bone marrow transplant could arrest such a severe neurological syndrome such as Rett is quite unexpected and provides us with yet another strong example of how tractable this disorder appears to be – at least in the animal models. Experiments are now underway in the Kipnis lab to test whether reversal of advanced symptoms via bone marrow transplants and other modulation of the immune system is also possible.
This work was funded by the Rett Syndrome Research Trust and the Rett Syndrome Research Trust UK.
The clinical relevancy of this work makes this paper of obvious and significant interest. But the authors don’t stop there. The paper describes data that could help us better understand how MeCP2 deficiency leads to symptoms. They introduce the concept of a powerful connection between the immune system and Rett Syndrome and open the door not only to bone marrow transplants as a treatment modality but potentially to other immune therapies as well.
To help you understand the key findings and implications we invite you to watch the videos below. Please watch the animation of the experiments first followed by the interview.
We would like to take this opportunity to thank Jeff Canavan of NewsAnimation for volunteering his time and effort to create the beautiful animation below. Jeff has a daughter with Rett Syndrome and founded, with his wife Sarah, the Kate Foundation for Rett Syndrome Research.
ANIMATION OF EXPERIMENT
We thank Jeff Bemiss for donating his filmmaking expertise, substantial time, energy, equipment and editing resources to film the interview below. He comes to our cause through his friendship with the Canavan family.
INTERVIEW WITH RESEARCHERS
Rett Syndrome Research Trust Interview Series
Yet Another Door Opens: Neuroimmunology
Considering Microglia, T Cells and Bone Marrow Transplants in Rett Syndrome
Today we interview Jonathan Kipnis, PhD, a neuroimmunologist who is looking at how the immune system interacts with the nervous system in Rett Syndrome, and is experimenting with ways to engage that interaction to impact Rett symptoms. The immune system is complex and multifaceted, with inflammatory and anti-inflammatory actions and modulatory influences on various other substances, including neurotrophic factors such as BDNF, familiar to parents who follow Rett research. RSRT is supporting his innovative exploration of bone marrow transplants in Rett models.
MC: Tell us, if you would, a little about your background. I know you trained in Israel.
JK: Yes, I got my BSc, majoring in biology, at Tel Aviv University and then I was off to the Weizmann Institute of Science, which is a wonderful place to do research in Israel. I first worked in the laboratory of Moshe Oren, a very famous cell biologist, and then joined the lab of Michal Schwartz –who was a great mentor for many years– for my PhD, working on the role of the immune system reactions in CNS injuries. I stayed there for post-doctoral training, and then came to the US. I have been at UVA, the University of Virginia, since 2005 in the Department of Neuroscience, and I’m a member of the Carter Immunology Center, combining my passions for immunology and neuroscience.
MC: So when you decided to go into immunology, were you immediately drawn to neuroimmunology, or did your interest in the brain and CNS come later?
JK: No, no—actually I trained in the Department of Neurobiology, so everyone around me was a neurobiologist except for my mentor, who was trained as an immunologist and then as a neuroscientist, so she definitely inspired my interest and love of both fields. I joined Michal’s lab the year they discovered that T cells, which are a type of lymphocyte, if injected in the right number and at the right time after injury to the brain or the spinal cord, will actually improve the outcome and protect neurons from death.
MC: Do you place them directly into the spinal cord?
JK: No, you don’t have to do that; you just inject them and they find their own way into the spinal cord.
MC: Much in the same way, perhaps, that we hear about embryonic stem cells going to where they’re needed in the brain, for repair?
JK: Absolutely, yes.
Rett Syndrome as a Model
MC: So, how did you get involved with Rett Syndrome?
JK: Okay, so this is quite complicated— and here is some of the history. To get the benefit of T cells after CNS injury, you need to really boost the number of T cells. The endogenous response is not very efficient. But the unexpected finding was that the spontaneous response is tightly regulated and if it goes out of control, then those same protective cells can become destructive and induce an autoimmune disease. This made us think that maybe endogenous T cell response that barely supports the brain after injury might have a major role in the brain function under physiological conditions. So we did a “crazy” experiment – we took mice that have no adaptive immunity, namely T cells.
MC: These are genetically engineered mice without any T cells?
JK: Yes, they are a model for “bubble kids”. It’s called SCID, severe combined immunodeficiency. They have no lymphocytes. We were very surprised to find that these mice are impaired in many tasks involving learning and memory, and also in brain plasticity. Even more surprising was the fact that when we gave them T cells from wild-type mice by intravenous injection, and checked them again after two weeks, we found they were perfectly fine in their cognitive function! So by aiding immune-deficient mice with T cells we improved their brain function.
MC: That’s very interesting.
JK: Later on, we took wild-type animals as adults and removed their T cells, and saw that their brain function becomes impaired. We still don’t know exactly what the T cells are doing in the brain, although our recent paper suggests that T cells in the brain produce a soluble molecule, called interleukin 4 and through this molecule they regulate the levels of BDNF in the brain. Moreover, T cells regulate synaptogenesis, plasticity and neurogenesis, which have been shown to be impaired in the Rett syndrome.
I started to look at the “immunological” literature of Rett and encountered a wonderful paper from a group at UC Davis—-
MC: By Janine LaSalle?
JK: Yes. She showed that in Rett patients there’s a skew in X activation in lymphocytes. That is, they prefer the gene with the normal MECP2. They seem to need it for survival and function.
MC: Do you think that this skewing happens over time?
JK: Perhaps. It would be interesting to see the difference between very young patients and those who are older. My prediction would be that the lymphocyte skewing might increase as they age.
MC: I’ve wondered about that, too.
JK: Obviously there are many important ways that MECP2 affects the neurons, but if the T cells are malfunctioning then that may be part of the picture. So we looked at the Rett male mouse models and found that indeed their T cells are significantly impaired; they do not respond well to what we call the antigenic stimuli. So that was the beginning of our interest, which has continued to grow.
MC: So you were looking for a disease model that could help you with a hypothesis that you had, and Rett Syndrome had all the characteristics that interested you?
MC: As I’m sure you’re aware, there is an MECP2 duplication disorder. It’s seen in boys and those boys often die of infection. In Rett Syndrome we see more subtle issues with infection. It does seem that too much MECP2 causes immune problems. Do you have any thoughts on that?
JK: Well we don’t have in the lab the mouse model for the MECP2 duplication, so we haven’t yet worked with that. But what we do know is that MECP2 as a protein is very important to certain subtypes of T cells that modulate immune response, and those may be malfunctioning in one way in Rett Syndrome, and over-functioning in MECP2 duplication syndrome. At this point it is really pure speculation but I think there may be something there.
MC: There’s nothing in the literature, as you know, but anecdotal information I’ve gathered from families over the past ten years or so includes instances of very, very high white cell counts; stressors that seem to precipitate regression; changed affect in children who seem to do better in some ways during or after a fever. I know of some Rett children who are on IVIG, and although it is for recurrent infections, they also seem to do better neurologically, for instance in terms of movement disorder.
JK: That’s very interesting. There’s so much we don’t know because of the variations in X-inactivation in humans, it’s hard to control for that, and as you say, this really has never been studied properly.
MC: I’ve been hearing quite a bit lately about neuroimmune connections; it seems to be an area of study that is heating up. Can you give us some general history of the field?
JK: The whole field of neuroimmunology was pursued as a sub-field of pathology until the breakthrough discovery that autoreactive T cells could be beneficial. Now many groups are studying the protective function of T cells in different acute and chronic neurodegenerative conditions, such as CNS injury and stroke, Alzheimer’s, Parkinson’s, ALS and many other diseases. All have in common the fact that removal or suppression of T cells results in exacerbation of the disease progression. With our recent work that points to the role of T cells in the healthy brain, we’ve come to understand if you impair immune response you impair normal maintenance of the brain and thus affect cognitive function and probably also other functions of the brain. So what was once viewed as pathology is now being understood as physiology.
MC: How many labs worldwide do you think are working on neuroimmune issues?
JK: Oh, there are dozens and dozens, many working on the deleterious aspects of immune function, like in MS–multiple sclerosis– and fewer studying the more positive maintenance properties of the immune system. There are four (or even more) journals in the field, and several scientific organizations, such as the ISNI (International Society for Neuroimmunology), the PNIRS (Psychoneuroimmunology Research Society) and others. These meetings attract hundreds (probably over a thousand for the ISNI meeting) of participants.
Bone Marrow Transplant and Rett Syndrome
MC: There was a recent paper by Nobel Laureate Mario Capecchi, fascinating work that caught the attention of quite a few Rett parents, actually. He was able to reverse symptoms of OCD using a bone marrow transplant. Can you talk a little bit about this?
JK: Absolutely. It’s very interesting and it did not surprise us at all. As you know, we have four major types of cells in the brain: the neurons, the astrocytes, oligodendrocytes, and microglia. Microglia are very, very active participants in the brain but are not made in the brain; they come from hematopoietic stem cells in blood or bone marrow. So if you give the mice new bone marrow, after a time the microglia in the brain will be replaced by the new microglia.
As you’re aware, we did something very similar: we took bone marrow from Rett mice and put it into wild-type mice, and our preliminary results show the appearance of Rett symptoms. We are still in the process of characterizing them, but we see signs that plasticity is impaired and we are quantifying motor malfunction as well.
MC: And it’s going to be very interesting, obviously, when you do this the other way around, putting wild-type marrow into Rett mice.
JK: Yes, hopefully we’ll have something to report very soon.
MC: And will you be doing this with newborns? Would it also apply to mature mice?
JK: We will be modulating the immune system in four different ways. I suspect that if we see good effects in newborns, we will see them also in adults.
MC: What can you imagine as the best possible outcome of this work?
JK: Rett is a complex disorder; I am not suggesting it could be entirely cured through the immune components. But we know that these components do affect neurotrophic factors and how the neurons can function, so the hope is that we will see substantial improvement in some aspects of the disease. Rett Syndrome has really captured my attention and we are working as fast as we can to see where this will go.
MC: Thank you very much, and good luck with the experiments. We look forward to giving our readers an update on this novel approach as your work progresses.